| SENZA Stock | | | SEK 5.65 0.05 0.88% |
Executive
Ms. Anna Cherouvrier Hansson was Chief Commercial Officer at SenzaGen AB since 2017. Anna Cherouvrier Hansson holds a European Masters degree in Business Administration from Lund University and a Bachelors degree in Business Administration from the European Partnership of Business Schools, Groupe ESC Reims, France and Fachhochschule Reutlingen, Germany. Anna Cherouvrier Hansson has extensive experience in the pharmaceutical industry and has previously worked with commercialization and business development at a number of companies including Camurus AB and Invest in Skane AB. In addition, Anna Cherouvrier Hansson was one of four partners at Zitha Consulting AB, working on behalf of pharmaceutical companies and their commercialization strategies. She has international employment experience and has previously worked in Denmark, Luxembourg and Germany. since 2017.
| Age | 50 |
| Tenure | 8 years |
| Phone | 46 4 62 75 60 00 |
| Web | https://senzagen.com |
SenzaGen Management Efficiency
The company has return on total asset
(ROA) of
(0.1691) % which means that it has lost $0.1691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.3224) %, meaning that it generated substantial loss on money invested by shareholders. SenzaGen's management efficiency ratios could be used to measure how well SenzaGen manages its routine affairs as well as how well it operates its assets and liabilities.
SenzaGen AB has accumulated 714
K in total debt. SenzaGen AB has a current ratio of 12.81, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist SenzaGen until it has trouble settling it off, either with new capital or with free cash flow. So, SenzaGen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SenzaGen AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SenzaGen to invest in growth at high rates of return. When we think about SenzaGen's use of debt, we should always consider it together with cash and equity.
Similar Executives
SenzaGen AB, together with its subsidiary, markets, sells, and performs in vitro genomic allergen rapid detection sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals and cosmetic ingredients in Sweden and internationally. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden. SenzaGen is traded on Stockholm Stock Exchange in Sweden. SenzaGen AB (SENZA) is traded on Stockholm Exchange in Sweden and employs 29 people.
Management Performance
SenzaGen AB Leadership Team
Elected by the shareholders, the SenzaGen's board of directors comprises two types of representatives: SenzaGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SenzaGen. The board's role is to monitor SenzaGen's management team and ensure that shareholders' interests are well served. SenzaGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SenzaGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
SenzaGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SenzaGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for SenzaGen Stock Analysis
When running SenzaGen's price analysis, check to
measure SenzaGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SenzaGen is operating at the current time. Most of SenzaGen's value examination focuses on studying past and present price action to
predict the probability of SenzaGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SenzaGen's price. Additionally, you may evaluate how the addition of SenzaGen to your portfolios can decrease your overall portfolio volatility.